Type 2 diabetes mellitus (T2D) and Alzheimer disease (AD) are major public health burdens associated with aging. As the age of the population rapidly increases, a sheer increase in the incidence of these diseases is expected. Research has identified T2D as a risk factor for cognitive impairment and potentially AD, but the neurobiological pathways that are affected are only beginning to be understood. The rapid advances in neuroimaging in the past decade have added significant understanding to how T2D affects brain structure and function and possibly lead to AD. This article provides a review of studies that have utilized structural and functional neuroimaging to identify neural pathways that link T2D to impaired cognitive performance and potentially AD. A primary focus of this article is the potential for neuroimaging to assist in understanding the mechanistic pathways that may provide translational opportunities for clinical intervention.
Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
2.
HebertLEScherrPABieniasJLBennettDAEvansDA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119–1122.
3.
StumvollMGoldsteinBJvan HaeftenTW. Type 2 diabetes: pathogenesis and treatment. Lancet. 2008;371(9631):2153–2156.
4.
DartiguesJF. Alzheimer’s disease: a global challenge for the 21st century. Lancet Neurol. 2009;8(12):1082–1083.
5.
ReitzCBrayneCMayeuxR. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137–152.
6.
BraakHBraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82(4):239–259.
7.
ThompsonPMHayashiKMDuttonRA. Tracking Alzheimer’s disease. Ann N Y Acad Sci. 2007;1097(1):183–214.
8.
ColeARAstellAGreenCSutherlandC. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev. 2007;31(7):1046–1063.
9.
Sims-RobinsonCKimBRoskoAFeldmanEL. How does diabetes accelerate Alzheimer disease pathology?Nat Rev Neurol. 2010;6(10):551–559.
10.
ZhangYZhouBDengB. Amyloid-β induces hepatic insulin resistance in vivo via JAK2. Diabetes. 2013;62(4):1159–1166.
11.
ArvanitakisZSchneiderJAWilsonRS. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology. 2006;67(11):1960–1965.
12.
BeeriMSSilvermanJMDavisKL. Type 2 diabetes is negatively associated with Alzheimer’s disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005;60(4):471–475.
13.
Malek-AhmadiMBeachTObradovA. Increased Alzheimer’s disease neuropathology is associated with type 2 diabetes and ApoE ∊.4 carrier status. Curr Alzheimer Res. 2013;10(6):654–659.
14.
ExaltoLGWhitmerRAKappeleLJBiesselsGJ. An update on type 2 diabetes, vascular dementia and Alzheimer’s disease. Exp Gerontol. 2012;47(11):858–864.
15.
CukiermanTGersteinHCWilliamsonJD. Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–2469.
16.
FontbonneABerrCDucimetièrePAlpérovitchA. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care. 2001;24(2):366–370.
17.
KanayaAMBarrett-ConnorEGildengorinGYaffeK. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med. 2004;164(12):1327–1333.
18.
Van den BergEReijmerYDde BresserJ. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(1):58–65.
19.
BiesselsGJDearyIJRyanCM. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008;7(2):184–190.
20.
Van den BergEKloppenborgRPKesselsRPCKappelleLJBiesselsGJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta. 2009;1792(5):470–481.
21.
Van HartenBOostermanJMuslimovicDvan LoonB-JPScheltensPWeinsteinHC. Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. Age Ageing. 2007;36(2):164–170.
22.
Den HeijerTVermeerSEvan DijkEJ. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003;46(12):1604–1610.
23.
SchmidtRLaunerLJNilssonL-G. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes. 2004;53(3):687–692.
24.
KumarRAnsteyKJCherbuinNWenWSachdevPS. Association of type 2 diabetes with depression, brain atrophy, and reduced fine motor speed in a 60- to 64-year-old community sample. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2008;16(12):989–998.
25.
BiesselsGJKoffemanAScheltensP. Diabetes and cognitive impairment. Clinical diagnosis and brain imaging in patients attending a memory clinic. J Neurol. 2006;253(4):477–482.
26.
GoldSMDziobekISweatV. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia. 2007;50(4):711–719.
27.
StrachanMWReynoldsRMMarioniREPriceJF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol. 2011;7(2):108–114.
28.
BruehlHWolfOTSweatVTirsiARichardsonSConvitA. Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 2009;1280:186–194.
29.
WilletteAAXuGJohnsonSC. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care. 2013;36(2):443–449.
30.
ManschotSMBrandsAMvan der GrondJ. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes. 2006;55(4):1106–1113.
31.
MoranCPhanTGChenJ. Brain atrophy in type 2 diabetes: Regional distribution and influence on cognition. Diabetes Care. 2013;36(12):4036–4042.
32.
ReijmerYDvan den BergEde BresserJ. Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors. Diabetes Metab Res Rev. 2011;27(2):195–202.
33.
EspelandMABryanRNGoveasJS. Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the Women’s Health Initiative Magnetic Resonance Imaging studies. Diabetes Care. 2013;36(1):90–97.
34.
YauPLJavierDTsuiW. Emotional and neutral declarative memory impairments and associated white matter microstructural abnormalities in adults with type 2 diabetes. Psychiatry Res. 2009;174(3):223–230.
35.
HsuJLChenYLLeuJG. Microstructural white matter abnormalities in type 2 diabetes mellitus: a diffusion tensor imaging study. Neuroimage. 2012;59(2):1098–1105.
36.
ReijmerYDBrundelMde BresserJ. Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: a diffusion tensor imaging study. Diabetes Care. 2013;36(1):137–144.
37.
BullmoreETBassettDS. Brain graphs: graphical models of the human brain connectome. Annu Rev Clin Psychol. 2011;7:113–140.
38.
NagamachiSNishikawaTOnoS. Regional cerebral blood flow in diabetic patients: evaluation by N-isopropyl-123I-IMP with SPECT. Nucl Med Commun. 1994;15(6):455–460.
39.
SabriOHellwigDSchreckenbergerM. Influence of diabetes mellitus on regional cerebral glucose metabolism and regional cerebral blood flow. Nucl Med Commun. 2000;21(1):19–29.
40.
TiehuisAMVinckenKLvan den BergE. Cerebral perfusion in relation to cognitive function and type 2 diabetes. Diabetologia. 2008;51(7):1321–1326.
41.
BrundelMvan den BergEReijmerYDde BresserJKappelleLJBiesselsGJ. Cerebral haemodynamics, cognition and brain volumes in patients with type 2 diabetes. J Diabetes Complications. 2012;26(3):205–209.
42.
van den BergEReijmerYDde BresserJKesselsRPKappelleLJBiesselsGJ. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(1):58–65.
ThambisettyMBeason-HeldLLAnY. Impaired glucose tolerance in midlife and longitudinal changes in brain function during aging. Neurobiol Aging. 2013;34(10):2271–2276.
45.
BakerLDCrossDJMinoshimaSBelongiaDWatsonGSCraftS. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51–57.
46.
GreiciusMKrasnowBReissAMenonV. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100(1):253–258.
47.
KellyCBiswalBBCraddockRCCastellanosFXMilhamMP. Characterizing variation in the functional connectome: promise and pitfalls. Trends Cogn Sci. 2012;16(3):181–188.
48.
ZhouHLuWShiY. Impairments in cognition and resting-state connectivity of the hippocampus in elderly subjects with type 2 diabetes. Neurosci Lett. 2010;473(1):5–10.
49.
MusenGJacobsonAMBoloNR. Resting-state brain functional connectivity is altered in type 2 diabetes. Diabetes. 2012;61(9):2375–2379.
50.
XiaWWangSSunZ. Altered baseline brain activity in type 2 diabetes: a resting-state fMRI study. Psychoneuroendocrinology. 2013;38(11):2493–2501.
51.
BiesselsGJDe LeeuwFELindeboomJBarkhofFScheltensP. Increased cortical atrophy in patients with Alzheimer’s disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry. 2006;77(3):304–307.
52.
ThambisettyMMetterEJYangA. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2013;70(9):1167–1172.
53.
CraftSFosterTCLandfieldPWMaierSFResnickSMYaffeK.SessionIII: Mechanisms of age-related cognitive change and targets for intervention: inflammatory, oxidative, and metabolic processes. J Gerontol A Biol Sci Med Sci. 2012;67(7):754–759.
54.
NelsonPTSmithCDAbnerEA. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta. 2009;1792(5):454–469.
55.
CraftSPeskindESchwartzMWSchellenbergGDRaskindMPorteDJr. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50(1):164–168.
56.
McNayECOngCTMcCrimmonRJCresswellJBoganJSSherwinRS. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol Learn Mem. 2010;93(4):546–553.
57.
RegerMAWatsonGSGreenPS. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70(6):440–448.
58.
CraftSBakerLDMontineTJ. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29–38.
59.
LuchsingerJASmallSBiesselsGJ. Should we target insulin resistance to prevent dementia due to Alzheimer disease?Arch Neurol. 2011;68(1):17–18.
60.
WatsonGSCholertonBARegerMA. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13(11):950–958.
61.
GoldMAldertonCZvartau-HindM. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131–146.
62.
HsuCCWahlqvistMLLeeMSTsaiHN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24(3):485–493.
63.
ImfeldPBodmerMJickSSMeierCR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc. 2012;60(5):916–921.
64.
MooreEMManderAGAmesD. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013;36(10):2981–2987.
65.
HunterKHölscherC. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
66.
DuringMJCaoLZuzgaDS. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173–1179.
67.
McCleanPLParthsarathyVFaivreEHölscherC. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci Off J Soc Neurosci. 2011;31(17):6587–6594.
